Applying stem cell technology for cardiovascular indications is not just an idea anymore.

CardioCell is currently in clinical trials using stem cells to develop highly effective, “off-the-shelf” therapeutic products for cardiovascular indication. These treatments will address the high, unmet medical needs in:

  • Acute Myocardial Infarction (AMI)
  • Chronic Heart Failure (CHF)
  • Peripheral Artery Disease (PAD)

For clinical trials, CardioCell is using cGMP allogeneic stem cells derived from the bone marrow of healthy volunteers. Manufactured in a licensed cGMP-compliant facility, the cells have been proven to be safe by Phase I clinical trials.

Our Parent Company
CardioCell's products use stem cells manufactured by its parent company, Stemedica Cell Technologies Inc. Regulatory agencies in multiple countries have licensed and approved Stemedica's clinical-grade stem cell manufacturing and clinical trial applications. For more information, please visit www.stemedica.com.
Clinical Trials Update
Northwestern University’s Phase IIa clinical trial for chronic heart failure of non-ischemic cardiomyopathy is currently enrolling new patients in the Chicago area. All participants will receive CardioCell's stem cell treatment. For more information, CLICK HERE.
Latest News
CardioCell launches trial to assess stem cell therapy for chronic HF. The initiation of a phase 2a trial of ischemia-tolerant stem cell therapy for patients with chronic HF due to nonischemic cardiomyopathy has been announced. READ FULL ARTICLE.